FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer

The authors investigate the implications of the 2023 FIGO staging system for early-stage endometrial cancer, particularly how upstaging may lead to overtreatment and increased toxicity without clear benefits on cancer outcomes. They highlight the lack of guidance in current NCCN guidelines for managing patients who are upstaged and call for further research to establish appropriate treatment protocols for these new stage subsets.